Breast cancer research : BCR · 2026
CAF-derived exosomes drive trastuzumab resistance in HER2-positive breast cancer via YAP-USP8-HER2 axis activation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yu Weijia, Jiang Li
Аннотация
BACKGROUND AND OBJECTIVE: Cancer-associated fibroblasts (CAFs), critical constituents of the tumor microenvironment, promote tumor progression and therapeutic resistance through exosome secretion. However, the mechanisms by which CAF-derived exosomes contribute to trastuzumab resistance in HER2-positive breast cancer remain unclear. This study investigated whether CAF-derived exosomes activate the YAP-USP8 axis to stabilize HER2 and induce trastuzumab resistance.
METHODS: Primary CAFs and normal fibroblasts (NFs) were isolated from HER2-positive breast cancer specimens, and exosomes were characterized by TEM, nanoparticle tracking analysis, and immunoblotting of exosomal markers. HER2-positive breast cancer cells (HCC1954 and BT-474) were treated with CAF- or NF-derived exosomes in vitro. Mechanistic studies were performed mainly in HCC1954 cells, whereas BT-474 cells were used for validation. Cargo dependency was assessed using RNase/Proteinase K protection assays, and YAP pathway involvement was examined using Verteporfin. In vivo tumor growth was evaluated using xenograft models.
RESULTS: CAF-derived exosomes reduced LATS1 and YAP phosphorylation (p < 0.001), enhanced nuclear YAP accumulation, and upregulated USP8 transcription, leading to HER2 stabilization (P < 0.001). Membrane disruption abolished Hippo suppression, indicating dependence on intravesicular cargo. CAF-exo treatment increased proliferation, elevated trastuzumab IC50, reduced apoptosis, and accelerated tumor growth in vivo (all p < 0.001). These effects were reproduced in BT-474 cells and were reversed by YAP or USP8 silencing. Pharmacological inhibition of YAP similarly restored trastuzumab sensitivity. TCGA-BRCA analysis revealed positive correlations between YAP1 and USP8, and between USP8 and ERBB2, supporting the molecular relevance of this axis.
CONCLUSION: This study identified a novel CAF-exosome-YAP-USP8-HER2 signaling axis that drives trastuzumab insensitivity in HER2-positive breast cancer. Intervening in this pathway may represent a potential treatment approach to counteract microenvironment-induced chemoresistance.
METHODS: Primary CAFs and normal fibroblasts (NFs) were isolated from HER2-positive breast cancer specimens, and exosomes were characterized by TEM, nanoparticle tracking analysis, and immunoblotting of exosomal markers. HER2-positive breast cancer cells (HCC1954 and BT-474) were treated with CAF- or NF-derived exosomes in vitro. Mechanistic studies were performed mainly in HCC1954 cells, whereas BT-474 cells were used for validation. Cargo dependency was assessed using RNase/Proteinase K protection assays, and YAP pathway involvement was examined using Verteporfin. In vivo tumor growth was evaluated using xenograft models.
RESULTS: CAF-derived exosomes reduced LATS1 and YAP phosphorylation (p < 0.001), enhanced nuclear YAP accumulation, and upregulated USP8 transcription, leading to HER2 stabilization (P < 0.001). Membrane disruption abolished Hippo suppression, indicating dependence on intravesicular cargo. CAF-exo treatment increased proliferation, elevated trastuzumab IC50, reduced apoptosis, and accelerated tumor growth in vivo (all p < 0.001). These effects were reproduced in BT-474 cells and were reversed by YAP or USP8 silencing. Pharmacological inhibition of YAP similarly restored trastuzumab sensitivity. TCGA-BRCA analysis revealed positive correlations between YAP1 and USP8, and between USP8 and ERBB2, supporting the molecular relevance of this axis.
CONCLUSION: This study identified a novel CAF-exosome-YAP-USP8-HER2 signaling axis that drives trastuzumab insensitivity in HER2-positive breast cancer. Intervening in this pathway may represent a potential treatment approach to counteract microenvironment-induced chemoresistance.
Предметные рубрики MeSH
HumansExosomesTrastuzumabFemaleBreast NeoplasmsDrug Resistance, NeoplasmAnimalsErb-b2 Receptor Tyrosine KinasesCancer-Associated FibroblastsYAP-Signaling ProteinsMiceEndosomal Sorting Complexes Required for TransportCell Line, TumorTranscription FactorsAdaptor Proteins, Signal TransducingXenograft Model Antitumor AssaysUbiquitin ThiolesteraseTumor MicroenvironmentSignal TransductionGene Expression Regulation, NeoplasticAntineoplastic Agents, Immunological